Sanofi-Aventis S.A. ADR (SNY) Stock Price, Quote & News

Company Profile

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscienti...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 33 1 53 77 40 00

Website: www.sanofi.com

Address:

46, avenue de la Grande ArmEe, Paris, France

DifferentRadar Jun. 4 at 2:58 PM

$NVAX $SNY Even if they only get 25% and Moderna gets 75% (which I have a hard time seeing) that means 3B and yearly royalties of $400+ million. We’re profitable at roughly $300 million going forward.

0 · Reply

ajbski Jun. 4 at 2:53 PM

$NVAX Nuvaxovid + Flu Vaccine (CIC) with $SNY poised to capture a large percentage of a $12B CIC market.

0 · Reply

GreenEnergy7B Jun. 3 at 9:33 AM

$ALT "Weight-loss drugs can cut breast cancer risk by up to 30%, studies suggest" "The first study, a retrospective analysis of 110,000 women aged between 45 and 80, found those who took GLP-1 medications were 30% less likely to develop breast cancer than those who did not." https://www.theguardian.com/science/2026/jun/02/weight-loss-drugs-cut-cancer-risk-studies $NVO $PFE $AZN $SNY

0 · Reply

JEDI_2023 Jun. 2 at 3:49 PM

$SNOW $SNY AI is now your Regional Sales Mgr. https://youtu.be/zCf46yHIzSo?si=6kEB5AXAx3GxLnJO AI Replacing Applications: Snowflake Cortex AI, including Snowflake CoWork and AI workflow partner Elementum, power AI directly on Sanofi's data Proven in the Field: Sanofi's new "Concierge for Field" agent equips sales reps with AI-generated pre-call plans in seconds.

0 · Reply

rp6577 Jun. 1 at 8:21 PM

$TLSA watching this again and it makes you very excited to get to September and the SPMS data. Multiple Pharma wanting to be first in line to see the data. What that means is that they will be competing with each other. A deal is going to get done as a result. Whether it’s a partnership or a buyout. Big Pharma are going to want Foralumab in their portfolio. $XBI $LABU $SNY

1 · Reply

jonztown Jun. 1 at 4:06 PM

$LOW $PG $SNY Flushing quality dividend large caps. Nice buying opportunity

0 · Reply

clan Jun. 1 at 2:20 AM

$MNKD Great news for diabetic kiddos!!! FDA APPROVED - - - AFREZZA For the good of all MannKind! T1Ds and Type 2s are NOW ready for the future! Inhalable mealtime insulin! Wow! 😲😃 $LLY $NVO $SNY

0 · Reply

clan May. 31 at 3:27 PM

$LLY 😲 Wow ! 😲 Diabetics Unite ! ✊️ Ultra Rapid-Acting INHALABLE Mealtime Insulin! 🚫💉 Who knew this exists ?!? Now FDA approved for kids!!! $SNY $NVO $SPY

0 · Reply

clan May. 30 at 10:03 PM

$SNY $LLY $NVO ⚠️ FDA Approval ⚠️ Inhalable ultra rapid-acting mealtime insulin. Great for the kids! $SPY

0 · Reply

clan May. 30 at 6:51 PM

$CIPLA.NSE $LLY $SNY 🇮🇳 Inhalable mealtime insulin - Afrezza - now approved in India. 🇮🇳 Adult-tested, kid tested; both approved!

0 · Reply

Press Release: Sanofi launches 2026 global employee stock purchase plan

Jun 3, 2026, 12:15 PM EDT - 1 day ago

Sanofi Transcript: Jefferies Global Healthcare Conference 2026

2026-06-02T15:53:47.000Z - 2 days ago

Sanofi (SNY) Unveils AI-Driven Sales Support Tool

2026-06-02T14:30:23.000Z - 2 days ago

Snowflake says Sanofi selects Snowflake Cortex AI for drug development

SNOW SNY

2026-05-28T11:40:15.000Z - 7 days ago

Sanofi (SNY) Receives FDA Priority Review for Venglustat Application

2026-05-28T09:59:23.000Z - 7 days ago

Market Cap	103.77B
Revenue (ttm)	52.85B
Net Income (ttm)	8.84B
EPS (ttm)	N/A
PE Ratio	9.36
Forward PE	8.63
Profit Margin	16.72%
Debt to Equity Ratio	0.25

Volume	1,334,905
Avg Vol	2,801,142
Day's Range	N/A - N/A
Shares Out	2.42B
Stochastic %K	31%
Beta	0.34
Analysts	Sell
Price Target	$55.01